IGV-001 is under clinical development by Imvax and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IGV-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IGV-001 overview
IGV-001 is under development for the treatment of glioblastoma multiforme. The drug candidate is an autologous tumor cell vaccine which consists of IGF-1R antisense oligodeoxynucleotide-treated glioma cells encapsulated in diffusion chambers implanted in rectus sheath. It is being developed based on Goldspire immuno-oncology platform. The drug candidate was under development for the treatment of malignant glioma.
Imvax overview
Imvax is a biotechnology company that develops immunotherapies to treat solid tumors. The company’s major product includes IGV-001, IHC-001, IEC-001, IUC-001, IOC-001, ICC-001 drug candidates. Its products are used to treat various tumors like malignant glioblastoma, hepatocellular carcinoma, endometrial cancer, urothelial cancer and ovarian cancer The company’s proprietary technology platform collects affected living cells from the tumors and treats them with IMV-001, an IGF-1R antisense oligodeoxynucleotide, by improving immune response. It collaborates with Sidney Kimmel Cancer Center to improve the safety and efficiency of its technology. The company markets its products under the brand name of Imvax. Imvax is headquartered in Philadelphia, Pennsylvania, the US.
For a complete picture of IGV-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
